Skip to content

Stuart Poulton, EVP, Chief Development Officer at Karyopharm Therapeutics, sold KPTI on Jul 28, 2026

Data as of Oct 16

▼ SELL$1.3K189 shares at $7.10Stuart Poulton EVP, Chief Development OfficerKPTI Karyopharm Therapeutics Inc.
Watch KPTI
Traded
Jul 28, 2026
Disclosed
Jul 30, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Stuart Poulton, EVP, Chief Development Officer at Karyopharm Therapeutics, sold KPTI on Jul 28, 2026TRADEDDISCLOSED
KPTISimilar stocks (XLV — its sector index fund), rebased to KPTI's price on the disclosure day
KPTI since disclosure
−94.4%
after the sale
Similar stocks (XLV) since disclosure
+8.1%
XLV — its sector index fund

Change in closing price from Jul 30, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

See every trade on KPTI →